INTRODUCTION AND OBJECTIVES:
To determine the safety of a restrictive transfusion protocol (RTP) in patients radical cystectomy (RC) patients that are typically elderly with significant co-morbidity, given that perioperative blood transfusion (PBT) has been linked to poorer oncologic outcomes in this setting.
METHODS: Outcomes for 173 consecutive patients meeting inclusion criteria undergoing RC for urothelial carcinoma (UC) from April 2010 to June 2014 by a single surgeon employing RTP were analyzed from an IRB approved, prospectively collected database.
RESULTS: Outcomes for 173 consecutive patients meeting inclusion criteria undergoing RC for urothelial carcinoma (UC) from April 2010 to June 2014 by a single surgeon employing RTP were analyzed from an IRB approved, prospectively collected database. Results: Median follow-up was 3.1 years (range¼0-5.1 years). Median age was 70 years RFS (HR¼2.16, CI [1.13, 41 .12], p¼0.02) ( Figure 1 ) and OS (HR¼2.25, CI [1.25, 4 .88], p¼0.01)( Figure 2 ). CONCLUSIONS: The use of RTP in RC is safe. PBT was associated with poorer RFS and OS independent of clinicopathologic characteristics.
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INTRODUCTION AND OBJECTIVES: Previous studies have been inconclusive whether the receipt of perioperative allogeneic blood transfusion (PBT) independently confers an impaired oncological outcome in patients treated with radical cystectomy (RC) for high-grade recurrent or muscle-invasive bladder cancer. Aim of this study was to evaluate the effect of perioperative PBT at RC on recurrence-free (RFS) and overall survival (OS) and cancer-specific (CSM) and other-cause mortality (OM) in a contemporary European multicenter cohort.
METHODS: We relied on the Prospective Multicenter Radical Cystectomy Series (PROMETRICS), which includes data of 679 patients undergoing RC at 18 European tertiary care centers in 2011. Patients with missing information on PBT, American Society of Anesthesiologists (ASA) physical status, follow-up, survival data, or disease recurrence, as well as clinically metastatic patients were excluded from further analyses. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e671
The association between PBT and oncological outcomes, as well as OCM was assessed using Cox and logistic regression analyses. Imbalances in clinicopathological features of patients receiving PBT vs. patients not receiving PBT were mitigated using conventional adjusting as well as inverse probability of treatment weighting (IPTW (RC) . We aim to evaluate these outcomes in open radical cystectomies (ORC) and robotic assisted radical cystectomies (RARC) reported in the National Cancer Data Base adjusted by surgery type.
METHODS: Using the National Cancer Data Base, patients treated with RC from 2003 to 2010 were identified. We evaluated the association between 90-day conditional mortality and readmission with respect to surgery type, adjusted by patient (age, gender, race/ethnicity, Charlson-Deyo score, tumor type, clinical stage, margin status and receipt of neoadjuvant chemo-or radiotherapy) and facility characteristics (overall cystectomy volume and facility type [Academic/Research, Comprehensive Community, or other]).
RESULTS: 16,923 RC cases (13,236 ORC, 3,687 RARC) were identified with 480 deaths (3.6%) after ORC and 99 deaths (2.7%) after RARC within 90 days, conditional upon surviving 30 days post-surgery. Comparing <3 cystectomies/year to >20 cystectomies/year, 90-day overall conditional mortality rates decreased from 4.0% to 2.5%. In stratified analyses, 90-day conditional mortality rates decreased from 4.2% to 2.7% for ORC and 2.7% to 2.0% for RARC. Center volume was strongly associated with 90-day conditional survival (p¼0.002), independent of surgery type. In multivariable analysis of 90-day conditional mortality, age (OR¼1.03, 95% CI: 1.02-1.04, p<0.0001), comorbidites (OR¼1.4, 95% CI: 1.12-1.6, p¼0.0005), margin rates (OR¼3.5,95% CI: 2.9-4.3, p<0.0001) as well as facility volume (OR¼0.99, 95% CI: 0.98-1.00, p¼0.001), were predictive of 90-day conditional mortality. Cystectomy volume did not predict 30 day readmission, however, Charlson-Deyo score 1-2 (OR¼1.274, 1.112-1.461 95% CI, p¼0.0005) and receipt of neoadjuvant chemo-or radiotherapy (OR¼1.161, 1.032-1.307 95% CI, p¼0.0134) were significantly associated with 30-day readmission.
CONCLUSIONS: Patients were less likely to incur death following robotic or open cystectomy within 90 days as institutional cystectomy volume increased. 30 day readmission rates were not influenced by institutional cystectomy volume. Recently, utilization of prophylactic dosed post-discharge subcutaneous enoxaparin has been reported to decrease VTE rates following radical cystectomy. We compared the rates of VTE following radical cystectomy at post-operative day 90 during three separate eras where patients received either prophylaxis with warfarin , subcutaneous heparin (2009-2012) while hospitalized, or subcutaneous heparin followed by 30-days of subcutaneous enoxaparin (2013-2015) following discharge.
METHODS: We used a prospectively maintained database to identify all patients who underwent radical cystectomy for primary bladder cancer with intent to cure at our institution from 1985-2015. Rates of VTE during the three different eras of VTE prophylaxis were calculated and compared. Multivariable logistic regression modeling was used to identify independent risk factors for VTE following radical cystectomy.
RESULTS: 2694 patients were identified during this time period and 168 patients were excluded for missing data. A total of 4.43% (n¼112, 57 DVT only) patients developed VTE. Rates of VTE were not significantly different between methods of VTE prophylaxis, (p¼0.8673). Multivariable logistic regression analysis identified age (OR 1.027, 95% CI 1.003-1.051), BMI (OR 1.073, 95%CI 1.034-1.113), non-orthotopic diversion (OR 0.456, 95%CI 0.261-0.794), and hospital length-of-stay (OR 1.038, 95%CI 1.011-1.064) to be independent predictors of VTE. CONCLUSIONS: VTE rates in patients treated with extended post-discharge prophylactic dosed subcutaneous enoxaparin were not significantly different than VTE rates in patients treated with warfarin or subcutaneous heparin while hospitalized at 90 days post-operatively. Age, BMI, non-orthotopic urinary diversion, and hospital length-of-stay were independent predictors for VTE in patients following radical cystectomy. These results conflict with recently published reports and highlight the need for a randomized controlled trial for VTE prophylaxis following radical cystectomy.
